ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.498,38
0,32%
S&P 500
5.187,67
0,00%
Dow Jones
39.056,39
0,44%
Euro vs US Dollar
1,07458
-0,04%
Bitcoin
61.498,71
-1,35%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Aridis Pharmaceuticals Inc (ARDS)

  7. Aridis Pharmaceuticals Inc (ARDS) News

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARDS
DatumZeitQuelleÜberschriftSymbolFirma
14/02/202402h02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
16/01/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
15/12/202322h15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202322h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202321h15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202311h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
14/09/202303h47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
07/09/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
25/08/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
04/08/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
04/08/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
03/08/202322h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202314h17GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
21/07/202312h49Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
20/07/202323h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
17/07/202322h05GlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
17/07/202321h01Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
17/07/202313h36Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
12/07/202314h00GlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
23/06/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
20/06/202314h00GlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
15/06/202323h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
15/06/202323h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
15/06/202323h13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
15/06/202323h10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202312h13Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
08/06/202322h05GlobeNewswire Inc.Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
31/05/202314h00GlobeNewswire Inc.Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignNASDAQ:ARDSAridis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARDS

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
CCOM
SILVER
SILVER
AMEX
SPY
SPDR S&P 500
DBI
DAX
DAX
FX
EURJPY
Euro vs Yen
TG
MBG
MercedesBenz
TG
BAYN
Bayer
TG
RHM
Rheinmetall
TG
432
Arbor Metals
FX
EURGBP
Euro vs Sterling
NASDAQ
AAPL
Apple
NYSE
NKE
Nike
FX
EURUSD
Euro vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
TG
D7G
Nel ASA
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten